Ann: Lumos Business Momentum Continues Following ASX Listing, page-2

Short interview today with LDX CEO on the FY21 rev increase + OEM partner EUA approval in US market. Nothing new shared.

CEO reiterated near-term focus continues to be scaling up US production chain, FebriDx commercialisation and overall capacity

+
a short article where LDX is mentioned:

2 Aug'21 - Who’s winning and losing in the life sciences IPO Olympiad?
_{https://unauthorised investment advice/health/dr-borehams-crucible-whos-winning-and-losing-in-the-life-sciences-ipo-olympiad/} (remove * in link)

"Only two weeks earlier Lumos Diagnostics (ASX:LDX) listed on the back of its fingerprick blood test to diagnose respiratory diseases. Lumos shares have held their ground, valuing the company at a cool $187 million.

As has been the experience with IPOs more broadly – and there’s been a spate of them – the only distinct trend from the Covid-era biotech listings is that there’s no distinct trend.We would like to say there’s a distinct pattern between how the drug developers have performed vis-a-vis the diagnostics or device plays, but there’s not."